Please join Gain Therapeutics for a virtual key opinion leader (KOL) event discussing current thinking on biomarkers, clinical outcome scales, and other endpoints to contextualize recent data from GT-02287 presented at the International Congress of Parkinson’s Disease and Movement Disorders^®, demonstrating disease modifying potential in Parkinson’s Disease patients with or without a GBA1 mutation.

Participating KOLs:

• Karl Kieburtz, M.D., M.P.H – Professor of Neurology, University of Rochester, Former Chair of the FDA Peripheral and Central Nervous System Drugs Advisory Committee
• Kenneth Marek, M.D – President and Senior Scientist, Institute for Neurodegenerative Disorders, Special Scientific Advisor to The Michael J. Fox Foundation

A live question and answer session will follow the formal presentations.